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A209Abstracts
Bosentan and N-carbamyl-L-glutamic acid obtained MA con-
textually to European market access; Imatinib obtained MA 
in Italy ﬁrst, one year after designation, and 3 years later in
Europe. Reimbursement and use are generally limited to hospi-
tal setting, except for Arsenic Trioxyde (at full patient’s charge)
and Bosentan (also in the outpatient setting). Four drugs 
(rH-interferon-gamma-1b, Mifepristone, Tetrahydrobiopterin,
Trientine-dichloride) were designated only few years after the
inclusion in the “Law-648” list (1998–2000); Idebenone con-
textually achieved OD status; Gemtuzumab and Galsulfase
within 1–5 years. CONCLUSIONS: The OD designation by
EMEA doesn’t necessarily imply Italian MA: 6% of European
ODs have currently accessed the Italian clinical practice. As 
elsewhere in Europe, procedures regulating authorisation and
funding criteria aren’t fully disclosed yet.
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OBJECTIVE: This paper compares the categories of therapeutic
improvement assigned to new medicines by the pricing/reim-
bursement authorities in Canada and France. In Canada the
Patented Medicine Prices Review Board (PMPRB) uses a system
of three categories to assess level of improvement. In France the
Commission de la Transparence of the Haute Autorité de Santé
(HAS) evaluates the degree of improvement (l’amélioration du
service médical rendu or ASMR) offered by each the new therapy
using a scale of six categories of improvement. METHODS:
From the PMPRB web site and publications, we identiﬁed 61
new active substances (NAS) categorized by the PMPRB since
2001. Of these, 36 also have an ASMR rating published by the
HAS and it is these 36 products that form the basis of the analy-
sis. RESULTS: The HAS classiﬁed 11 (30.6%) of the 36 prod-
ucts as offering a major or important advance (ASMR I or II)
whereas the PMPRB identiﬁed only 3 (8.3%) as providing a
breakthrough or substantial improvement (Category 2). The
PMPRB classiﬁed 33 (91.7%) of the 36 products as offering
moderate, little or no improvement (Category 3). Of these 33
products, the HAS classiﬁed 8 as offering a major or important
advance (ASMR I & II), 10 as a moderate advance (ASMR III),
and 15 as providing minor or no improvement (ASMR IV, V &
VI). CONCLUSIONS: There appears to be considerable dispar-
ity between the French and Canadian rating systems as to what
constitutes a clinically signiﬁcant improvement in pharmaceuti-
cal therapy. Moreover, the French system appears more likely to
recognize important advances and, unlike the Canadian system,
is designed to distinguish incremental improvement. The differ-
ences noted above may be due to several factors including the
criteria and thresholds used to determine improvement, time of
introduction, availability of important comparator therapies and
standards of clinical practice.
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OBJECTIVES: The use of pharmacoeconomic evaluation in for-
mulary, reimbursement and pricing decisions has been widely
used and accepted throughout the world. However, the extent of
its use and acceptance by the pharmaceutical industry in Saudi
Arabia is still lacking. The objective of this study was to assess
current trend and attitude toward the use of such studies by the
pharmaceutical industry in a country where the health care
spending is considered to be one of the highest in the Middle
East. METHODS: A mailed survey to all major pharmaceutical
companies was send between April and June 2006. The survey
was directed to general, sales and marketing managers in these
companies. The survey contained questions that measured the
manager’s knowledge, opinion and use of pharmacoeconomic
techniques in formulary, pricing and marketing of pharmaceuti-
cals in Saudi Arabia. RESULTS: More than 80% of the respon-
ders believe that pharmacoeconomics should be used when
making formulary and pricing decisions. However, the extent of
its use by these companies is very limited. The source of infor-
mation, in companies where pharmacoeconomic have been used
in the past, was mainly from published literature. CONCLU-
SIONS: Despite the study ﬁnding that indicate that pharmaceu-
tical companies are in favor of the use of pharmacoeconomics
its use is still very rare. Factors that may be behind this limited
use is the lack of regulations and requirements in both the public
and private sectors. The lack of experts and consultants may also
play an important role in this problem. In Saudi Arabia, the
pharmaceutical industry should invest more in this important
ﬁled to help them show the real value of there products.
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OBJECTIVES: The cost structure of ostomy appliances tends to
be a black box and has not been investigated in the international
literature to date. Little information is available about the rela-
tionship between pricing and reimbursement of ostomy appli-
ances in Belgium. The aim of this study is to develop a model
that calculates the cost of production and distribution of ostomy
appliances and to explore whether Belgian reimbursement tariffs
correspond with estimated costs of ostomy appliances.
METHODS: The analysis focused on basic models of one-piece
and two-piece colostomy and ileostomy appliances that are com-
monly sold in Belgium by six international manufacturers. A cost
model was developed to estimate manufacturing costs, costs of
overhead, R&D, warehousing and proﬁts associated with the
production of ostomy appliances. Multiplying these product
costs with a factor representing distribution margins in Belgium
generated an estimate of retail prices of ostomy appliances. The
cost model was populated with data from manufacturers, a
decomposition of ﬁnished products, and interviews with stake-
holders. RESULTS: The cost model yielded estimated retail
prices of €2.96 for one-piece appliances, € 1.62 for two-piece
pouches, and €2.06 for two-piece ﬂanges. Distribution costs
accounted for 60% of retail prices and product costs made up
40%. Estimated retail prices corresponded well with tariffs of
€3.10 for one-piece appliances and € 1.56 for two-piece pouches.
For two-piece regular ﬂanges, a substantial difference was
observed between the calculated price of €2.06 and the Belgian
tariff of €6.05. CONCLUSIONS: In the absence of publicly dis-
closed information on the cost structure of appliances, estimates
of production and distribution costs of ostomy appliances can
be used by national reimbursement agencies to set tariffs.
